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THE BAYH-DOLE ACT AND INCENTIVES FOR THE
COMMERCIALIZATION OF GOVERNMENT-FUNDED
INVENTION IN DEVELOPING COUNTRIES
Michael S. Mireles*
I. INTRODUCTION
Numerous developing and developed countries are considering adopting or
have adopted legislation similar to the U.S. Bayh-Dole Act.1 Enacted in 1980,
the Bayh-Dole Act attempts to provide incentives for potential participants in the
creation and development of government-funded technology to commercialize
that technology. 2 The Act has been controversial, and whether developing and
developed countries that enact similar legislation will realize the same purported
impact the Act has had in the United States is questionable. This article provides
an analysis of some of the provisions of the Act in light of its alleged effects in
the United States since its enactment and offers some suggestions for
modification of the Act for developing countries This paper also proposes that

* Assistant Professor, Sturm College of Law, University of Denver. The author is grateful for the
support of the editorial staff of the UMKC Law Review. The author also greatly appreciates the
comments of Gary Pulsinelli, Srividhya Ragavan, and Peter K. Yu and the research assistance of
Diane Burkhardt, Caryl Shipley, Evan Aspinwall, Margo Chan, Dan Christopherson, Vivian Chu,
Mia Fiedler, Ryan Fletcher, and Daniel Staley.
1 Bayh-Dole University and Small Business Patent Procedures Act, Pub. L. No. 96-517, 94 Stat.
3015 (1980) (codified as amended at 35 U.S.C. §§ 200-212 (2000)).
2 See 35 U.S.C. § 200 (identifying the statute's policy and objective).
3 There is no universal definition of what constitutes a "developed" or "developing" country, even
though those terms are used within the World Trade Organization (WTO) system. See Sungjoon
Cho, The WTO's Gemeinschaft, 56 ALA. L. REv. 483, 487 n.18 (2004) ("There is no official
definition of 'developing countries."'); Leah Granger, Explaining the Broad-Based Supportfor
WTO Adjudication, 24 BERKELEY J. INT'L L. 521, 521 n.3 (2006) ("There is no universally accepted
definition for a 'developing' or 'developed' country, and this is a very rough division. Developing
countries are a diverse group, varying in physical size, population, and resources."); Doris Estelle
Long, "Democratizing" Globalization:Practicingthe Policies of Cultural Inclusion, 10 CARDOZO
J. INT'L & COMP. L. 217, 222 n.13 (2002) ("Admittedly, the terms 'developed' and 'developing'
lack clear definitions and suffer from being both over- and under-inclusive."); Eugenia McGill,
Poverty and Social Analysis of Trade Agreements: A More Coherent Approach?, 27 B.C. INT'L &
COMP. L. REV. 371, 373 n.2 (2004) ("Classifications of countries as 'developed,' 'developing,' and
'least developed' are similarly contested and fluid and can vary from one context to another.");
World Trade Organization, Who are the developing countries in the WTO?,
Developing
WTO
[hereinafter
http://www.wto.org/english/tratop_e/devele/d1whoe.htm
Countries] ("There are no WTO definitions of 'developed' and 'developing' countries.") (last
visited Dec. 27, 2007). In fact, countries within the WTO may designate themselves as developing
and other countries may challenge that designation. See Cho, supra, at 487 n. 18 ("Countries often
declare themselves to be developing countries, in which case other countries can challenge that
declaration. Within the WTO system, developing countries are treated more favorably than
developed countries under certain circumstances."); WTO Developing Countries, ("Members
announce for themselves whether they are 'developed' or 'developing' countries. However, other
members can challenge the decision of a member to make use of provisions available to developing
countries."). An additional category, "least developed country," has been created by the United
Nations and is also used by the WTO. See Cho, supra, at 487 n.18 ("In the case of Least
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the adoption of the Act in developing countries could lead to an increased focus
on commercializing technology directed to the local needs of developing
countries. However, enactment of similar legislation in a developing country is
unlikely to have the same purported impact on a similar scale in that developing
country as the Bayh-Dole Act has had in the United States-substantially
increased patenting and licensing and other related economic activity.
Commentators in the United States have been debating the merits of the
Bayh-Dole Act, which allows recipients of government funding to take title to
inventions developed with that funding, and its purported consequences since the
Act's inception. Some argue that the Act has a deleterious impact on the
creation, direction and dissemination of basic scientific research, particularly in
the biotechnology field,4 and that it facilitates the development of conflicts of

Developed Countries (LDCs), the UN officially designated 50 countries as the LDCs."); World
Trade
Organization,
Least-developed
countries,
http://www.wto.org/english/thewtoe/
whatis e/tif e/org7_e.htm (identifying the thirty-two designated LDCs that are WTO members)
(last visited Dec. 27, 2007); UN Office of the High Representative for the Least Developed
Countries, Landlocked Developing Countries and Small Island Developing States,
http://www.unohrlls.org/ [hereinafter UN Office for LDCs] (last visited Dec. 27, 2007). The
criteria for LDC status includes:
a low-income criterion, based on a three-year average estimate of the gross national
income (GNI) per capita (under $745 for inclusion, above $900 for graduation);
a human capital status criterion, involving a composite Human Assets Index (HAI)
based on indicators of: (a) nutrition ... ; (b) health ... ; (c) education ... ; and (d)

adult literacy rate; and an economic vulnerability criterion, involving a composite
Economic Vulnerability Index (EVI) based on indicators of: (a) population size; (b)
remoteness; (c) merchandise export concentration; (d) share of agriculture, forestry
and fisheries in gross domestic product; (e) homelessness owing to natural disasters;
(f) instability of agricultural production; and (g) instability of exports of goods and
services.
To be added to the list, a country must satisfy all three criteria. In addition, since the
fundamental meaning of the LDC category, i.e. the recognition of structural
handicaps, excludes large economies, the population must not exceed 75 million. To
become eligible for graduation, a country must reach threshold levels for graduation
for at least two of the aforementioned three criteria, or its GNI per capita must exceed
at least twice the threshold level, and the likelihood that the level of GNI per capita is
sustainable must be deemed high.
UN Office for LDCs, Least Developed Countries: Criteria for identification of LDCs,
http://www.unohrlls.org/en/ldc/related/59/ (last visited Dec. 27, 2007).
In this article, the term "developed countries" includes the United States, European Union
countries, Japan, South Korea, Canada, and Australia. It is the author's belief that countries
designated as "least developed countries" by the United Nations may receive little benefit from the
passage of legislation similar to the Bayh-Dole Act. Though those countries that are not developed
and are not categorized as "least developed" by the United Nations may receive some benefit from
legislation similar to the Bayh-Dole Act, generalizations are difficult to make because of the
diversity among those countries in terms of size, resources, and political stability.
4 See Michael A. Heller & Rebecca S. Eisenberg, Can Patents DeterInnovation? The Anticommons
in Biomedical Research, 280 SCIENCE 698 (1998).

2007]

BA YH-DOLE ACT & DEVELOPING COUNTRIES

interest, which may impact public health. 5 Thus far, there is insufficient and
somewhat conflicting empirical evidence of whether a tragedy of the
anticommons-the inability to aggregate the patents covering various
technologies needed to develop a product or process--exists in the biotechnology
6
Some posit that the Federal Circuit's decision in Madey v. Duke
sector.
University,7 which narrowly interprets the common law experimental use
exception to patent infringement, may contribute to the development of an
anticommons.
There is also conflicting empirical evidence on whether the
Bayh-Dole Act has affected the direction of academic research from basic to
applied science. However, some specific examples of conflicts of interest have
arisen, which cause concern about the effect the Act has had on the integrity of
academic research. Supporters of the Act point to an upswing in universities'
patenting and licensing government-funded inventions, along with other related
economic activity (such as the creation of new companies and jobs) since passage
of the Act. 9 Others argue that those effects would have occurred without passage

5 See Michael S. Mireles, States as Innovation System Laboratories:California,Patents, and Stem
Cell Technology, 28 CARDozo L. REV. 1133, 1174 (2006); Joshua B. Powers, Between Lab Bench
and Marketplace: The Pitfalls of Technology Transfer, CHRON. HIGHER EDUC., Sept. 22, 2006, at
B18; DEREK BOK, UNIVERSITIES IN THE MARKETPLACE:

THE COMMERCIALIZATION OF HIGHER

EDUCATION 215 (2003).
6 See, e.g., Charles McManis & Sucheol Noh, Impact of the Bayh-Dole Act on Genetic Research

and Development: The Empirical Evidence to Date (reviewing empirical evidence concerning
anticommons) (unpublished manuscript, on file with author); STEPHEN HANSEN ET AL., THE EFFECTS
(2006), available at
COMMUNITY
7
AAAS
SCIENTIFIC
PATENTING
IN
THE
OF
http://sippi.aaas.org/survey/AAAS IP SurveyReport.pdf [hereinafter AAAS REPORT] (last visited
Dec. 27, 2007); NAT'L INSTITUTES OF HEALTH, REPORT OF THE NATIONAL INSTITUTES OF HEALTH
at
(1998),
available
TOOLS
GROUP
ON
RESEARCH
(NIH)
WORKING
http://www.nih.gov/news/researchtools/ (last visited Dec. 27, 2007); NAT'L RESEARCH COUNCIL,
REAPING THE BENEFITS OF GENOMIC AND PROTEOMIC RESEARCH: INTELLECTUAL PROPERTY RIGHTS,

INNOVATION, AND PUBLIC HEALTH (2006) [hereinafter REAPING THE BENEFITS]; John P. Walsh et al.,

Effects of Research Tool Patents and Licensing on Biomedical Innovation, in PATENTS IN THE
KNOWLEDGE-BASED ECONOMY 285 (Wesley M. Cohen & Stephen A. Merrill eds., Nat'l Research
Council 2003); Fiona Murray & Scott Stem, Do Formal Intellectual Property Rights Hinder the
Free Flow of Scientific Knowledge? An Empirical Test of the Anti-Commons Hypothesis 6 (Nat'l
11465, 2005), available at
Bureau of Econ. Research, Working Paper No.
http://www.nber.org/papers/w 11465 (last visited Dec. 27, 2007); Bhaven N. Sampat, Genomic
5-6
(2004),
for
Science?
Researchers:
Bad
by
Academic
Patenting
http://mgt.gatech.edu/newsroom/news/2004/reer/files/sampat.pdf.
7 307 F.3d 1351 (Fed. Cir. 2002).
8 REAPING THE BENEFITS, supra note 6; see also FED. TRADE COMM'N, To PROMOTE INNOVATION:

THE PROPER BALANCE OF COMPETITION AND PATENT LAW AND POLICY 35 (2003), available at
http://www.ftc.gov/os/2003/l0/innovationrpt.pdf ("[T]he . . . [Madey decision] could unsettle

expectations regarding the availability of an experimental use defense and could have a chilling
effect on university research." ).
9 See W. Mark Howell, Messagefrom the President in ASS'N OF UNIV. TECHNOLOGY MANAGERS,
at
(2005),
available
FY
2004
LICENSING
SURVEY:
AUTM
U.S.
http://www.autm.net/events/File/04AUTMSurveySum-USpublic.pdf (last visited Dec. 27, 2007);
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of the Act. I0 At least one commentator argues that the fundamental decision to
allow universities to take title to government-funded inventions was a mistake
because of the subsequent mismanagement of government funding and abuse of
licensing position and income by universities."
Notwithstanding these debates and the lack of conclusive empirical
evidence concerning the impact of the Act, other countries, developed and
developing, are considering adopting legislation similar to the Bayh-Dole Act in
order to achieve the same purported benefits of the Act. 12 Some commentators
have argued that the Bayh-Dole Act may not achieve the same purported level of
success-success defined as increased patenting and licensing of governmentfunded inventions and related economic activity-in developed, Organisation of
Economic Co-operation and Development [OECD] countries for several reasons.
Those reasons focus on the existence of factors in the United States not always
present in other developed countries: the close link between universities and the
private sector; the structure and scale of the university system; the existence of
technology transfer offices well before the passage of the Act; and the presence
of the demand from industry for technology transfer because of "venture capital,
labor mobility between university and industry, large scale public funding for
biomedical research, competition between universities for faculty and research
money, lack of central government control and administrative autonomy of
universities in addition to a comprehensive patent system."' 3 In a recent essay, I
U.S. DEP'T OF COMMERCE, THE ADVANCED TECHNOLOGY PROGRAM: REFORM WITH A PURPOSE 11

(2002), availableat http://www.atp.nist.gov/secyrept/report.pdf (last visited Dec. 27, 2007).

10 DAVID C. MOWERY ET AL., IVORY TOWER AND INDUSTRIAL INNOVATION: UNIVERSITY-INDuSTRY

TECHNOLOGY TRANSFER BEFORE AND AFTER THE BAYH-DOLE ACT 1 (2004).

1"Lorelei Ritchie de Larena, The Price of Progress: Are Universities Adding to the Cost?, 43
Hous. L. REv. 1373, 1390-91 (2007).
12 See Michael S. Mireles, Adoption of the Bayh-Dole Act in Developed Countries:Added
Pressure
for a Broad Research Exemption in the United States?, 59 ME. L. REV. 259 (2007); Ken Howard,
Global Biotech Expansion Taking Cuesfrom Bayh-Dole, 22 NATURE BIOTECH. 919 (2004). South
Africa, Malaysia, and the Philippines are considering or have adopted legislation similar to the
Bayh-Dole Act. See Chris Bull, Managing Intellectual Assets at Universities: The South African
Government is Considering the Introduction of Legislation Similar to the US Bayh-Dole Act
Governing IP Arisingfrom University R&D, MANAGING INTELL. PROP., Apr. 1, 2005, availableat
http://www.accessmylibrary.com/coms2/sumniary_0286-6541410_ITM (last visited Dec. 28,
2007); South Africa: Should SA Follow US Lead on Patent Laws?, AFRICA NEWS, Jan. 13, 2004;
Local Scientists Hope to Reap Benefits via New Research Law, MALAYSIA ECON. NEWS, Oct. 29
2004.
13Howard, supra note 12, at 919-20; see also David C. Mowery & Bhaven N. Sampat, The BayhDole Act of 1980 and University-Industry Technology Transfer: A Model for Other OECD
Governments?, 30 J. TECH. TRANSFER 115, 118-19 (2005) (identifying the unique structure of the
U.S. higher educational system and its effect on academic patenting). For additional discussion of
differences between market structure and other factors in the United States and other developed
countries, see Michael R. Darby & Lynne G. Zucker, Star Scientists, Institutions, and the Entry of
Japanese Biotechnology Enterprises(Nat'l Bureau of Econ. Research, Working Paper No. 5795,
1996), availableat http://www.nber.org/papers/w5795 (last visited Dec. 28, 2007) ("Some authors
have also specifically discussed the various differences between the United States and Japanese
systems concerning 'higher education and research funding, the venture-capital and IPO markets,
cultural characteristics and incentive systems which impact scientists' entrepreneurialism, and tort-
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described how OECD countries are attempting to address some of those issues in
order to improve the rate of commercialization of government-funded inventions
and to encourage related economic activity by attempting to facilitate
collaborations between industry and universities, changing university structure
and incentives for researchers, and providing venture capital support.'I propose
that OECD countries will achieve some level of success in the form of increased
patenting and licensing of government-funded inventions, which may result in
pressure on the United States for the adoption of a more robust experimental use
exception.15 Negative consequences of the Act in the form of the development of
an anticommons may be avoided in some OECD countries because of the
presence of an experimental use exception
16 to patent infringement that is broader
than its counterpart in the United States.
The chance for success of legislation similar to the Bayh-Dole Act in
developing countries seems to be bleak, particularly considering that similar
success may not occur in developed countries that have access to far more
resources than developing countries. In addition to the lack of a history of
technology transfer and collaboration between industry and academia, a similar
scale of university systems, and analogous mobility among personnel between
universities and industry, developing countries may also not have access to other
resources necessary to establish a successful innovation system that utilizes
legislation similar to the Bayh-Dole Act to encourage commercialization. An
innovation system that includes a grant of title to a government-funded invention,
as the Bayh-Dole Act is premised upon, likely requires at least a substantial level
of government funding to support research and development; a well-established
and functioning patent system; qualified technology transfer personnel and
researchers; favorable corporate formation, initial public offerings, and
competition laws; and ample venture capital. The presence of these factors may
be fundamental to the success of an innovation system predicated on capturing
the supposed benefits of a Bayh-Dole scheme, although it is very difficult to
make generalizations about developing countries at various levels of economic
growth and political stability.'7 This article first provides some lessons from the
liability exposures."');
AT

UNIVERSITIES

ANNA S. NILSSON ET AL., COMMERCIALIZATION OF LIFE-SCIENCE RESEARCH
IN THE UNITED STATES, JAPAN AND CHINA 27 (2006), available at

http://www.itps.se/Archive/Documents/Swedish/Publikationer/Rapporter/Allmanna/A2006/A2006_
006%20webb.pdf (last visited Dec. 28, 2007) ("Japanese pharmaceutical companies tend to do
more in-house basic research and to a lesser extent rely on alliances with biotechnology companies
or universities" than their European or U.S. counterparts); and Thomas J. Siepmarm, The Global
Exportation of the US. Bayh-Dole Act, 30 U. DAYTON L. REv. 209, 218 (2004) (indicating that
European researchers may be more risk adverse in commercializing research because of the small
number of positions in.European universities and that there may be a greater incentive in the United
States to commercialize because of the lack of government price controls on pharmaceuticals).
14Mireles, supra note 12, at 265.
I" Id. at
161id.

273-76.

17 Some additional impediments to the success of legislation similar to the Bayh-Dole Act in
developing countries could include corruption, conflicts of interest, the lack of a contracting culture
and negotiation skills, the lack of markets within the developing country, and the lack of interest in
commercialization.
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United States experience with the Bayh-Dole Act and proposes some suggestions
for change based on those lessons. It then sets forth one possible consequence to
developing countries of passage and implementation of legislation similar to the
Bayh-Dole Act.
II. THE BAYH-DOLE ACT AND ITS PURPORTED CONSEQUENCES:
LESSONS FOR DEVELOPING COUNTRIES
Commentators have provided suggestions for reform of the Bayh-Dole Act
based on its purported impact on biotechnology innovation. Commentators have
also proposed reform to general patent law principles, in part in response to the
Bayh-Dole Act's impact. One timely and excellent article by Sara Boettiger and
Alan Bennett examines the possible implications for developing countries of the
adoption of the Bayh-Dole Act in the United States and also the possible
ramifications of the adoption of legislation similar to the Bayh-Dole Act in
developing countries. Is This paper discusses and analyzes that paper, along with
other scholarship concerning the impact of the Act and proposals for its reform,
including best practices for licensing government-funded technology.
A. The Bayh-Dole Act
The Bayh-Dole Act provides incentives for parties to engage in the
commercialization of government-funded research. The primary incentive
provided by Bayh-Dole is the ability of grant recipients, usually universities, to
take title to government-funded inventions, subject to certain conditions.19 Some
of these conditions on obtaining title to government-funded inventions include
accepting reporting requirements, a grant-back license, and march-in rights.2 °
The Act gives inventors an incentive to disclose patentable inventions through
the possibility that they will receive some royalties from the successful license of
patented technology.2' This prospect of royalties also gives inventors an
incentive to continue to work on commercializing the technology with industry.
The Act's implementing regulations require that the university develop a policy
to encourage disclosure of patentable inventions by its researchers. 2 The
university has an incentive to create and monitor that policy and facilitate

18 Sara Boettiger & Alan Bennett, The Bayh-Dole Act: Implicationsfor Developing Countries, 46

IDEA 261 (2006).
19 COUNCIL ON GOVERNMENTAL RELATIONS, UNIVERSITY TECHNOLOGY TRANSFER, QUESTIONS AND

ANSWERS 1 (1996), available at http://206.151.87.67/docs/bayhdoleqa.htm (last visited Jan. 4,
2008). "When a university elects title to an invention, it assumes responsibility for taking certain
actions to properly manage the invention." University of California Technology Transfer, The
Bayh-Dole
Act,
A
Guide
to
the
Law
and
Implementing
Regulations,
http://www.ucop.edu/ott/faculty/bayh.html (last visited Jan. 4, 2008).
20 ALINE C. FLOWER, INTELLECTUAL PROPERTY TECHNOLOGY TRANSFER 17-18 (2006) (citing 37
C.F.R. § 401.14(0(2) (2005)).
21 See id. at 19-20.
22

Id.
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licensing of patentable inventions because of the opportunity to recover licensing
fees and royalties. The university is also likely the party best positioned to front
patent prosecution costs, as an inventor is unlikely to have the resources
(although the licensee of government-funded technology tends to reimburse the
university for costs expended). The market actor/licensee has an incentive to
obtain technology that has been developed through government funding because
it may be able to acquire technology, including a possible exclusive license,
without having to invest in the creation of that technology. The Bayh-Dole Act
eliminated the ability of individual government grantor entities to develop their
own policy for the ownership of government-funded technology and provided a
uniform policy for the treatment of that technology.24
The basic provisions creating these incentives are likely to be adopted by
developing countries that adopt legislation similar to the Bayh-Dole Act. Some
provisions that may be modified by developing countries include a research
exemption to increase access to government-funded inventions, expanded and
specific march-in rights, and the right to a royalty stream to the government that
is providing the funding. Other issues include the adoption of mandatory
licensing best practices, which may be included in the developing country BayhDole Act legislation, and structuring technology transfer offices as regional or
national offices instead of having institutional offices. Still other concerns
include attempts to learn from and avoid the possible negative impacts of the
Bayh-Dole Act seen in the United States, such as the effect of the Act on the
direction and dissemination of research and the creation of conflicts of interest in
academia. Some of these concerns are addressed by Sara Boettiger and Alan
Bennett's article and the work of other commentators, which are reviewed and
analyzed below.
B. Lessons from the Bayh-Dole Act and Its Purported Impact
This section reviews and analyzes issues concerning access to governmentfunded technology that have arisen since passage of the Bayh-Dole Act in the
United States, and potential issues that may develop because of the adoption of
similar legislation in other developed countries and in developing countries. This
section also analyzes the question of whether developing countries should adopt
national, regional or institutional technology offices or some combination, and

23

See

INTELLECTUAL

TECHNOLOGY,

PROPERTY

STUDY

GROUP,

CALIFORNIA

COUNCIL

ON

SCIENCE

AND

POLICY FRAMEWORK FOR INTELLECTUAL PROPERTY DERIVED FROM STEM CELL

RESEARCH IN CALIFORNIA: INTERIM REPORT TO THE CALIFORNIA LEGISLATURE, GOVERNOR OF THE
STATE OF CALIFORNIA, CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE 10 (2005), available at

http://www.ccst.us/publications/2005/1Pinterim.pdf (last visited Jan. 4, 2008) [hereinafter CCST
INTERIM REPORT] (suggesting that California should adopt Bayh-Dole Act policies which place
patenting costs with the entity most likely able to bear them).
24 See The University and Small Business Patent ProceduresAct: Hearing on S. 414 Before the S.
Comm. on the Judiciary,96th Cong. 2 (1979) (statement of Sen. Birch Bayh); id. at 30 (statement
of Sen. Robert Dole); id. at 33 (statement of Sen. Orrin G. Hatch).
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other issues related to technology transfer that may impact the success of
legislation similar to the Bayh-Dole Act in developing countries.
1.

Access to Government-Funded Technology

Some of the most controversial issues concerning the Bayh-Dole Act
include access to government-funded technology by third parties who either need
to access the technology to continue to innovate and create a product, or require
the technology for an end use purpose such as use of the technology to treat a
disease (which may include access to a pharmaceutical that has been developed
in part with government funding or with technology created with government
funding). One potential issue involves whether grant recipients under the BayhDole Act or similar legislation in developed countries will create licensing
policies and practices that take into account the needs of developing countries to
have access to government-funded technology in both cases described above.
Second, the rise in patenting and licensing as a possible result of passage of the
Bayh-Dole Act and similar legislation in other developed countries could result
in an anticommons in the United States, other developed countries, and
developing countries. Third, provisions in the U.S. Bayh-Dole Act designed to
ensure access to government-funded technology have likely not been used as
frequently as expected by policymakers and those provisions could be used more
effectively to ensure access to government-funded technology for developing
countries-in the Bayh-Dole Act and in similar legislation in developed and
developing countries. Fourth, access to research materials covered by material
transfer agreements is a problem that apparently has risen in the United States
and may develop in developing countries. Finally, the decision to grant exclusive
versus non-exclusive licenses by grant recipients under the Bayh-Dole Act or
similar legislation in other developed or developing countries may result in
problems with access to government-funded technology for developing countries.
Boettiger and Bennett's article addresses some of the major issues
concerning the Bayh-Dole Act and access to government-funded technologies for
The article recognizes the difficulties in making
developing countries.
generalizations concerning developing countries, which have widely differing
economic conditions.25 Boettiger and Bennett assert that issues concerning
access to research tools and other basic research in biotechnology may have
negative implications for developing countries, particularly in the agricultural
field.26 A potential problem for developing countries is that university
technology transfer offices in the United States may not be considering the
interests of developing countries in accessing basic research, and undoing
existing licenses to allow access may be difficult if not impossible. Boettiger and
Bennett point to licensing language developed by the Public Intellectual Property
Resource for Agriculture and Universities Allied for Essential Medicines
designed to ensure that universities and other research institutions reserve rights

25

Boettiger & Bennett, supra note 18, at 262.

26

Id. at 265-66.
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to allow access for "humanitarian commercial development, that benefits the
poor and underserved. ' '27 Developing countries adopting Bayh-Dole Act
legislation should consider creating licensing rules that reserve the right to
provide access specifically for humanitarian reasons. This reservation may in
some cases undercut the value of the patent rights because the only commercial
market for some patents may be other developing countries that have
humanitarian needs and want to access the technology. However, some basic
research conducted in developing countries may have broad applicability and
there may be demand in developed countries for patents covering that basic
may have the resources to pay at
research. Moreover, some developing countries
28
least reduced prices to use the technology.
The next issue Boettiger and Bennett address concerns the creation of an
anticommons and whether the Madey v. Duke University29 decision, which
narrowly interprets the U.S. experimental use exception
•30 to patent infringement,
Commentators have
will contribute to the development of an anticommons.
argued that an anticommons may develop because of the Madey decision, and
many such commentators have also argued for the adoption of a broader
exception. 3 1 The empirical evidence of an anticommons is unclear. I recently

27

Boettiger & Bennett, supra note 18, at 265 (citing the Public Intellectual Property Resource for

Agriculture website, http://www.pipra.org/ and Universities Allied for Essential Medicines, Model
Access
and
Neglected
Disease
License,
Provisions
for
an
Equitable
http://www.essentialmedicine.orgEAL.pdf). Boettiger and Bennett also raise the open licensing
approaches proposed by Amy Kapczynski, Samantha Chaifetz, Zachary Katz & Yochai Benkler.
See Id. (citing Amy Kapczynski, Samantha Chaifetz, Zachary Katz & Yochai Benkler, Addressing
Global Health Inequities: An Open Licensing Approach for University Innovations, 20 BERKELEY
TECH. L. J. 1021 (2005)).
28 Some developing countries have negotiated lower fees for patented drugs with pharmaceutical
companies. See Kaisernetwork.org, Kaiser Daily HIV/AIDS Report, Drug Access, Brazilian
Official at Latin American Conference on AIDS Calls for Countries to Break Patents, Self-Produce
ARVs, Jan. 13, 2006, http://www.kaisemetwork.org/dailyreports/repindex.cfm?DRID=34778
(last visited Jan. 4, 2008).
29 307 F.3d 1351 (Fed. Cir. 2002).
30Boettiger & Bennett, supranote 18, at 268.
31 See Rebecca S. Eisenberg, Patents and the Progress of Science: Exclusive Rights and
Experimental Use, 56 U. CHI. L. REv. 1017 (1989); Rochelle Dreyfuss, Protecting the Public
Domain of Science: Has the Timefor an Experimental Use Defense Arrived?, 46 ARIz. L. REv. 457
(2004); Janice M. Mueller, The Evanescent Experimental Use Exemptionfrom United States Patent
Infringement Liability: Implicationsfor University and Nonprofit Research and Development, 56
BAYLOR L. REv. 917 (2004); Janice M. Mueller, No "Dilettante Affair": Rethinking the
Experimental Use Exception to Patent Infringementfor Biomedical Research Tools, 76 WASH. L.
REv. 1 (2001); David L. Parker, Patent Infringement Exemptions for Life Science Research, 16
Hous. J. INT'L L. 615 (1994); Katherine J. Strandburg, What Does the Public Get?: Experimental
Use and the Patent Bargain, 2004 Wis. L. REv. 81 (2004); but cf Jordan P. Karp, Note,
Experimental Use as Patent Infringement: The Impropriety of a Broad Exception, 100 YALE L.J.
2169, 2179-83 (1991) ("A system with a broad experimental use allowance would have a disparate
impact on less well-financed inventors whose ability to conduct R&D may be limited in the short
term when they are not able to convince possible investors of the potential commercial success of
their patented inventions."); Heather Hamme Ramirez, Comment, Defending the Privatizationof
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argued that adoption of the Bayh-Dole Act in developed countries may lead to
increased patenting and licensing in the United States, which could lead to an
anticommons effect and subsequent pressure to adopt a broad experimental use
exception in the United States similar to that existing in some other developed
countries. 33 Whether adoption of Bayh-Dole Act legislation in developing
countries will contribute to an anticommons in those countries or in developed
countries is unclear and will likely depend on the breadth of the experimental use
exception to patent infringement in each of those countries, as well as the
presence and exercise of specific provisions in their Bayh-Dole legislation
concerning access. One solution to overcoming a potential anticommons within
a particular developing country would be to adopt a proposal recently made by
Professor Gary Pulsinelli to require that "[a]ll researchers whose work is
supported by federal funds should have a limited, royalty-free license to make
34
and use for research purposes all inventions developed with federal funds."
This proposal would create a research exemption that would include all recipients
of government funding in the developing country and might mitigate an
anticommons effect. Another option to possibly avoid an anticommons is to
adopt a broad research exemption to patent infringement. This may undercut the
value of the patent and create uncertainty as to the scope of the patent. However,
a broad research exemption within the Bayh-Dole Act type legislation seems to
be more justified than a general research exemption because the government has
already funded the creation
of the invention, at least to a stage where it is
35
protected by patent law.
While the Bayh-Dole Act in the United States attempts to take into account
the interests of all the relevant parties-the taxpayers who provide the funding,
the government, the researcher, the licensee and the licensor-the Act arguably
does not sufficiently protect the interests of the public in the United States. For
example, an "exceptional circumstances" provision designed to leave certain
Research Tools: An Examination of the "Tragedy of the Anticommons" in Biotechnology Research
and Development, 53 EMORY L.J. 359, 372-74 (2004); Richard J. Bauer, Comment, Why Not Try
the Experiment and Stop Pointing the Finger? Modern University Research Unaffected by a

Narrow Experimental Use Exception, 24 TEMP. J. Sci. TECH. & ENVTL. L. 121, 135 (2005) ("Yet in
practice, industry is not aggressively suing universities for patent infringement despite both a
university's greater than before vulnerability to patent infringement claims, and academic
scientists' pervasive and routine disregard for intellectual property rights." (citations omitted));
Elizabeth A. Rowe, The Experimental Use Exception to Patent Infringement: Do Universities

Deserve Special Treatment?, 57 HASTINGs L.J. 921, 954 (2006) ("The Madey court's narrow
interpretation of the experimental use exception is consistent with precedent, consistent with public
policy, and appropriate for university research.").
32Boettiger & Bennett, supra note 18, at 270-71; Mireles, supra note 5, at 1165-68.
33 Mireles, supranote 12, at 276-82.
34 Gary Pulsinelli, Share and Share Alike: Increasing Access to Government-FundedInventions
Under the Bayh-Dole Act, 7 MINN. J. L. Sci. & TECH. 393, 442-43 (2006). Boettiger and Bennett
also argue that "[d]evelopment of new policies should consider the inclusion of a well-reasoned
research exemption for university researchers' use of proprietary IP." See Boettiger & Bennett,
supra note 18, at 278.
35 See Michael S. Mireles, An Examination of Patents, Licensing, Research Tools, and the Tragedy
ofthe Anticommons in BiotechnologyInnovation, 38 U. MICH. J.L. REFORM 141, 211-16.
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37
36
government-funded inventions in the public domain and "march-in rights",
exist in the _present Bayh-Dole Act, but these provisions have been used
infrequently. The exercise of those provisions might also be used to prevent an
anticommons from forming in the United States or in other countries that adopt
similar legislation to the Bayh-Dole Act. Boettiger and Bennett also argue that
while there are protections in the Bayh-Dole Act for access to patented
technologies, such as march-in rights, similar compulsory licensing in legislation
adopted by developing countries may deter investment by the private sector.3 9
However, because of the scarcity of funding resources in developing countries,
the argument for access to government-funded technology has more force, and
ensuring that access through march-in rights or a similar provision (such as the
grant-back clause) is critical to ensuring that a government-funded technology is
available to the public. Furthermore, the prospect of compulsory licensing
already exists in developing countries as a result of provisions in TRIPS.
Moreover, march-in rights could be tailored to industry concerns and are also
helpful for ensuring that government-funded inventions are commercialized.
Another potentially troubling problem involves access to research materials
covered by material transfer agreements (MTAs).4 ° Some studies have found
that researchers are having trouble accessing materials covered by those
agreements in the United States. 4' In one study, 47% of researchers surveyed
reported difficulties in accessing data and materials held by other researchers.4 2
If researchers are reporting difficulties accessing materials covered by MTAs in
the United States, it is probable that researchers in developing countries will have
similar problems in obtaining materials from researchers in their country or other
countries. The solution to this problem for a particular country could be an
agreement by researchers receiving government funding from that country to
allow other researchers receiving government funding from that country to have

36

The government may determine that "exceptional circumstances" exist where the policies and

objectives of the Act are better served by the "restriction or elimination of the right to retain title to
any subject invention will better promote the policy and objectives" of the Act. 35 U.S.C. §
202(a)(ii) (2000). For additional discussion of the exceptional circumstances provision and a
proposal to modify that provision, see Arti K. Rai & Rebecca S. Eisenberg, The Public Domain:
Bayh-Dole Reform and the Progress of Biomedicine, 66 LAW & CONTEMP. PROBS. 289, 293-94,
310-13 (2003).
37 The government has the power to compel an owner of a patent on a government-funded
invention to license that invention when "(1) action is necessary because the [grantee] has not
taken, or is not expected to take within a reasonable time, effective steps to achieve practical
application of the subject invention in such field of use; [or] (2) action is necessary to alleviate
health or safety needs which are not reasonably satisfied by the [grantee]." 35 U.S.C. § 203(a).
38 Mireles, supra note 5, at 1155-56, 1159. Boettiger and Bennett argue that "the inclusion of
'march in' rights has the potential for creating uncertainty in IP rights ownership and therefore may
discourage industry involvement." Boettiger & Bennett, supra note 18, at 279.
39Boettiger & Bennett, supra note 18, at 276.
40 See Mireles, supra note 5, at 1170-74.
41id.
42 Eric G. Campbell, et al., Data Withholding in Academic Genetics: Evidence from a National
Survey, 287 J.AM. MED. ASs'N 473, 473 (2002).
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access to materials or data created during government-funded research. This
proposal is somewhat similar to that offered by Professor Pulsinelli,4 3 but it is not
limited to government-funded patented inventions, including also research
materials and data that may not be covered by patents.
Another concern is the use of exclusive licenses, which would allow a
single licensee to control the exploitation of a government-funded invention. The
Bayh-Dole Act allows the recipient of government funding to grant exclusive
licenses in technology created with that funding.44 Exclusive licenses in
government-funded technology are particularly troublesome when examined in
light of the lack of use of the "march-in" and the general reluctance to use the
"exceptional circumstances" provisions in the Bayh-Dole Act designed to ensure
access to that technology. Instead of leaving the decision to the recipient of
government funding, the decision to patent and whether to grant a non-exclusive
or exclusive license could be left with the grantor of funding. 45 However, as
discussed by Professor Pulsinelli, there are intractable issues with attempting to
determine ex ante whether something should be patented or not, thus making
provisions like the "exceptional circumstances" provision in the Bayh-Dole Act
very difficult to use.46 Given the uncertainty that exists in research, particularly
biotechnology research, it may also be difficult to determine ex ante at the time
of funding whether an exclusive license may be necessary to commercialize a
government-funded invention. The National Institutes of Health's Best Practices
for the Licensing of Genomic Inventions and Guidelines for Recipients of NIH
Research Grants and Contracts on Obtaining and Disseminating Biomedical
Research Resources take a different approach and recommend that research tools
should be subject to non-exclusive licenses; however, these policies are voluntary
and not mandatory. 47 If the determination of whether to grant a non-exclusive or
exclusive license remains with the university, exclusive licenses should only be
granted when necessary to secure funding for commercialization. As Professor
Lemley has recently suggested, universities could use exclusive licenses with
field-of-use restrictions to minimize the impact of the exclusive license.4 8 The
use of negative milestones would also be helpful to ensure that technology that is
exclusively licensed will be commercialized.

43 See supra text accompanying note 34.
44 35 U.S.C. § 207(a)(2) (2000).
45 See Rai & Eisenberg, supra note 36, at 304-05, 310-11.
46 Pulsinelli, supranote 344, at 441.
47 Best Practices for the Licensing of Genomic Inventions: Final Notice, 70 Fed. Reg. 68 (Apr. 11,
2005); Principles and Guidelines for Recipients of NIH Research Grants and Contracts on
Obtaining and Disseminating Biomedical Research Resources: Final Notice, 64 Fed. Reg. 246
(Dec. 23, 1999).
48 Mark A. Lemley, Are Universities Patent Trolls? 14-16 (Stanford Public Law, Working Paper
No. 980776, 2007), available at http://papers.ssm.com/sol3/papers.cfm?abstractid=980776 (last
visited Jan. 5, 2008).
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2.

National, Regional, and/or Institutional Technology Transfer
Offices

Professor Lorelei Ritchie de Larena advocates that a national technology
transfer office should be created and given control over management of
government-funded technologies.49 She is critical of universities in the United
States and asserts that they are incompetent stewards of govemment-funded
invention. 50 She points to universities' failure to adhere to Bayh-Dole Act
mandates, such as reporting inventions, 51 university researchers misusing
government fundin, 52 and universities abusing their licensing position and
resulting revenue.
A study by the Inspector General indicated that
approximately 23% of the federally-funded inventions were not reported to the
government as required by Bayh-Dole.5 4 According to Professor Ritchie de
Larena, this "means that federal taxpayers are not even getting basic
governmental access to many of the inventions they fund."'5 Given these issues,
developing countries should ensure that if they require reporting requirements,
which they should require in order to track inventions developed by university
researchers with government funding, they should enforce compliance by
universities. This enforcement is particularly important for the government to be
able to exercise "march-in" rights whenever necessary.
Professor Ritchie de Larena further describes numerous instances of
universities and their researchers misusing government funding. 6 These abuses
include six major research universities in the United States that have "paid civil
fees to the government to settle charges of improper diversion of federal research
funds." 57 She argues that, "[t]he lack of oversight over faculty, coupled with the
pressures on them to compete for grants and produce exciting results, leads to a
culture where hard-core cheatin as well as softer ambiguities in interpretation
and presentation are common."
To address similar situations that may arise,
developing countries should also create ethics rules concerning the use of
government funding for research and the licensing of government-funded
inventions to mitigate issues concerning cheating.
Finally, Professor Ritchie de Larena points to the abuse of licensing
position and revenue by universities under the Bayh-Dole scheme.5 9 Some of
this abuse includes favoring faculty start-ups with licenses with inadequate

49Ritchie de Larena, supra note 11, at 1339-44.
50

See id. at 1389-91.
"' Id. at 1396-99.
52 Id. at 1402-10.
53
Id.at 1412.
54 Id. at 1399 (citing U.S. GEN. ACCOUNTING

OFFICE, TECHNOLOGY TRANSFER:

REQUIREMENTS FOR FEDERALLY SPONSORED INVENTIONS NEED REVISION 12-13 (1999)).
5

Id. at 1398.
1401-10.
Id. at 1406.
5
Id. at 1409.
59
Id. at 1412.
16Id.at
57
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consideration in return and attempting to extract overreaching payments for
licensing government-funded technology. 60 Universities may also attempt to use
patents on basic science to garner high licensing fees, 61 may over-patent possibly
contributing to an anticommons, 62 and may engage in "socially conscious
licensing"-licensing at low rates to organizations serving third world countries,
but reserving rights to industrialized countries-while still requiring those
organizations to pay patent expenses.63 Moreover, as discussed supra, to avoid
the possibility of the development of an anticommons, developing countries
should consider a research exemption similar to that proposed by Professor
Pulsinelli. 64 This exemption may also allow for "socially conscious" licensing
and help mitigate the impact of the possible development of an anticommons
generally. In addition, developing countries should consider legislating licensing
best practices to avoid some of the problems raised by Professor Ritchie de
Larena.
Professor Ritchie de Larena has proposed the development of a national
technology-transfer center in the United States.65 This center would provide
management services for all government-funded intellectual property and require
any commercial licensing entities to pay patent prosecution costs. 66 Under this
scheme, inventors would receive a portion of the licensing fee in exchange for
would go to
finding licensees, while "a smaller percentage [of licensing income]
,,17
Moreover,
the school or department and a nominal amount to the university.
funding normally held under Bayh-Dole by university administrators for
"indirect costs" would go to the national technology-transfer center for further
investment in research. 68 "[T]he center would have a Board of Advisors
consisting of university, government, legal and industry experts who would
review technology-specific portfolios quarterly and make suggestions on
commercialization"; in addition, "the center would maintain a public, Internet
database of all inventions and their licensing status [that] every government
"Any technology patented but not
contractor would have access to. . .,69
licensed within a reasonable period, would be dedicated to the public domain, so
as not to unduly encumber future research., 70 However, moving away from an
atomistic institutional scheme to a more centralized approach would create
certain concerns. For example, one of the benefits of the Bayh-Dole Act is that it

6

°Id.at 1416.
1418.
62 Id. at 1422-25.
63 Id. at 1421. Professor Ritchie de Larena further argues that "the very fact of having patent rights
61 Id. at

in [third-world] countries provides a bar to entry for potential competitors that might offer lowercost options on the university technology and improvements thereto." Id.
6 See supra text accompanying note 344.
65 Ritchie de Larena, supra note 11, at 1439.
61d.at 1440.
67 Id. at 1441.
68 Id.
69 Id. at 1443.
70 Id. (citation omitted).
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provides incentives for individual researchers to disclose their inventions and
continue involvement in the commercialization of the invention through the
promise of a royalty. The involvement of the inventor in the commercialization
of government-funded research is critical in many cases. 71 The Act also provides
incentives for universities to encourage researchers to engage in technology
transfer. Professor Ritchie de Larena's scheme may leave insufficient incentives
to prompt universities to encourage researchers to disclose inventions. However,
this problem could be cured by improved oversight by the grantor of the
government funding, which is also part of Professor Ritchie de Larena's
proposal.
Professor Kristen Osenga argues that Professor Ritchie de Larena's
approach fails to "suggest an intellectual property management strategy" for
universities, "provide [universities] with hows and whys of patent acquisition and
exploitation," or "provide the vital infrastructure necessary to create an effective
technology transfer office.",72 According to Professor Osenga, adopting an
approach that addresses these concerns will help alleviate problems concerning
access and funding for research and development.73 Professor Osenga advocates
that universities should embrace patenting and, importantly, decide on an
intellectual property strategy that includes focus on a particular strategy for what
inventions to patent and attempt to license.74 For developing countries, as
discussed infra, this could include focusing on creating inventions directed to
solving local problems. She also highlights the importance of having a welltrained staff to understand technology and commercialization trends to
implement the intellectual property strategy.7 5 The structure proposed by
Professor Osenga includes at least one patent attorney, personnel with technical
skill, and personnel with business expertise.76 However, as discussed infra,
access to qualified personnel may be difficult for some, if not most, developing
countries.
Depending on the resources in a developing country, the country may or
may not attempt to create technology transfer offices in each university. A
regional approach, similar to the one proposed by Jennifer Washburn,77 or the

71Mireles, supra note 5, at 1198.

Kristen Osenga, Rembrandts in the Research Lab: Why Universities Should Take a Lesson from
Big Business to IncreaseInnovation, 59 ME. L. REv. 407, 429 (2007).
71Id. at 436-37.
14 Id. at 429.
71Id. at 433-34.
76 id.
77 Jennifer Washburn, UNIVERSITY INC.: THE CORPORATE CORRUPTION OF HIGHER EDUCATION 22872

230 (2005).
[T]he federal government should take the initiative by establishing a series of
nonprofit technology-transfer hubs, located in different regions of the country, which
would handle the patenting and licensing needs of all the nation's universities and
colleges. These offices.., would operate under a federal mandate to carry out the
provisions of the Bayh-Dole Act. They would probably function best if they were
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national approach set forth by Professor Ritchie de Larena,78 may be helpful in
lowering the costs of funding a technology transfer office, and fewer technology
transfer offices would require fewer knowledgeable personnel to manage them.
"[A regional or national] structure also has the potential to sustain a 'commons'
of technologies in specific areas by aggregating IP and managing unified
portfolios of technologies under a common set of objectives., 79 National or
regional offices would reduce competition between institutional technology
transfer offices.8 °
Developing countries could experiment and utilize regional or national
offices to manage and license the intellectual property created in individual
institutions. Regional or national offices might be able to provide the benefits of
tracking the government-funded intellectual property, providing oversight over
all use of the government-funded intellectual property, and also managing any
revenues that may result from licenses from the government.8 ' A royalty for the
chartered, pseudogovermnental organizations that enjoyed considerable independence
and flexibility.
Id. at 229.
78 See Boettiger & Bennett, supra note 18, at 275. Boettiger and Bennett caution that there may not
be enough well-trained IP technology transfer professionals and that "[r]egional, rather than
institutional management of government-funded patents affords economies of scale in sustaining
the large costs and limited revenues of patent portfolios" and technology transfer offices. Id.
79 Id.
80

See id. at 280.

s Technology transfer offices, whether at the institutional, regional, or national level, can provide

the following benefits:
Protection of intellectualproperty. TTOs review new inventions by an institute's
research staff and assist them in determining the patent status of the technology.
Assigning a financial value to the research is important for approaching industry with
the aim of licensing the technology.
Revenues through licensing of intellectualproperty. TrOs can assess the commercial
potential of intellectual properties and market these technologies through licensing, so
as to generate new revenues for the institute. Licencing [sic] of technology involves
promotion and marketing, negotiation, implementation and execution of the actual
license agreement, including royalty payments.
Education and awareness. TrOs can conduct educational programmes to make
scientists and research administrators aware of the correct ways to handle new
inventions, including issues such as official lab books for record-keeping, confidential
disclosures, publication guidelines and agreements.
Networking. TrOs can stimulate networking by maintaining a database of new
technologies with commercial potential and sharing this with other institutes under
conditions of confidentiality. The office may also facilitate networking with
technology transfer associations, training and service organizations.
Creationof new start-up companies. TTOs can help in the establishment of new startup companies through links with venture capital firms in countries where these are
available. Office staff can help to address any conflicts of interest which may arise
between researchers' duties to their parent institutes and their spin-off company.
Institutionalpolicies related to technology transfer. TTOs can help develop and
enforce policies dealing with inventions, discoveries and intellectual properties that
are generated by the institute.
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university and researcher would be required by legislation and negotiable by the
parties to the license. Regional or national offices might also be helpful in
promoting collaborations of institutions within their region or the nation and in
coordinating research and development.82 For some developing countries,
technology transfer offices might also be able to track and catalogue indigenous
knowledge and biodiversity resources, creating a repository of prior art to prevent
patenting in other countries.
3.

Additional Issues Concerning Adoption of the Bayh-Dole Act in
Developing Countries

This section discusses additional issues concerning the adoption of the
Bayh-Dole Act in developing countries, including the possible impact of the Act
on the direction of academic research in the United States and elsewhere; the
historical lack of cooperation between industry and academia in developing
countries and the presence of other resources, such as a large amount of
government funding; the possible modification of provisions of the Bayh-Dole
Act for adoption in developing countries, including the manufacturing clause;
and the addition of new provisions concerning a royalty stream to the
government or contributors of indigenous knowledge or biodiversity resources,
and consequences for noncompliance with the legislation. Moreover, this section
analyzes issues concerning the ability of governments in developing countries to
use the prospect of government funding for research to leverage favorable pricing
for products developed with government-funded technology and the creation of
performance metrics for technology transfer that take into account factors besides
revenue generation and numbers of patents and licenses.
Boettiger and Bennett point out that "[1]ess than 10% of health research
funding is targeted at diseases that account for 90% of the global disease burden"
and that public research has historically been very important to the development
of inventions in the "health and agriculture [fields] that do not have commercial
Service to society. Society supports public institutes indirectly through the payment
of state and local taxes. TrOs may stimulate access to the knowledge and
biotechnologies developed in the institutes for the benefit of society.
Karim M. Maredia et al., Technology Transfer Offices for Developing Countries, 43 BIOTECH. &
DEVELOPMENT MONITOR 15, 16-17 (2000).
82 Halla Thorsteinsd6ttir et al., Commentary, Conclusions: PromotingBiotechnology Innovation in
Developing Countries, 22 NATURE BIOTECH. DC48, DC50 (2004) ("By encouraging collaborations
and resource sharing among different institutions in its innovation system, Cuba has been able to
succeed in health biotechnology, despite its very limited financial resources."). Brazil has been
successful in creating a virtual institute wherein researchers from thirty-four biology laboratories
and a bioinformatics research institute across Brazil were able to sequence "the genome of a plant
pathogen, Xylella fastidiosa, a bacterium that attacks citrus fruits." Marcela Ferrer et al., The
Scientific Muscle of Brazil's Health Biotechnology, 22 NATURE BIOTECH. DC8, DC 10 Box 1 (2004)
(citation omitted). However, Brazil has struggled with developing relationships between
universities and private industry, and between private companies. See id. at DC I I ("The Minister
of Science and Technology .. . [stated], 'Brazilians get lost between basic research and its
transformation into technology, between academic life and the manufacturing system.' A major
contributor to this problem is the lack of linkages among biotechnology firms.").
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markets. 83 Boettiger and Bennett express concern about the impact the BayhDole Act may have had upon the direction of academic research and whether an
increase in patenting is creating "impediments to research and humanitarian
applications of new technologies" or an anticommons effect. 84 First, empirical
evidence concerning whether the direction of academic research has been
affected by the opportunities to commercialize research is unclear. 85 The lure of
potential royalties and other economic rewards would seem to provide an
incentive for academic researchers to orient their research toward applied
research to solve problems where there are commercial markets,86 and therefore
whether the Bayh-Dole Act has had an impact on the direction of research should

83 Boettiger & Bennett, supra note 18, at 265.
8
4 Id at 266.
85

Id. at 266-67; see also Mireles, supra note 355, at 168-70 (discussing recent research and

potential impact of a shift in academic research from basic to applied research); McManis & Noh,
supra note 6, at 27 (arguing empirical evidence of shift in academic research is "mixed at best");
Jerry G. Thursby & Marie C. Thursby, University Licensing Under Bayh-Dole: What are the Issues
and Evidence? 5 (May 2003), available at http://opensource.mit.edu/papers/Thursby.pdf (last
visited Jan. 5, 2008) ("We find in a study of over 3400 faculty at 6 major research universities that
the basic/applied split in research did not change over the period 1983-1999 even though licsensing
[sic] had increased by a factor greater than 10 .... "); MOWERY ET AL., supra note 10, at 184 ("We
have uncovered little evidence that the expanded patenting and licensing activities of U.S.
universities since 1980 have produced significant shifts in the orientation of academic researchers
away from fundamental research toward more applied, short-term research activities that might be
more easily patented and licensed."); ScoTT SHANE, ACADEMIC ENTREPRENEURSHIP: UNIVERSITY
SPINOFFS AND WEALTH CREATION 282 (2004) ("While scholars of... technology transfer have not
found any direct evidence ...that the opportunity to found university spinoffs leads researchers to
focus on more applied research at the expense of basic science or to avoid research areas with
limited commercial potential, they have found indirect evidence of these effects."); cf Pierre
Azoulay et al., The Impact of Academic Patentingon the Rate, Quality, and Direction of (Public)
Research 2 (Nat'l Bureau of Econ. Research, Working Paper No. 11917, 2006), available at
http://www.nber.org/papers/wl1917 (last visited Jan. 5, 2008) ("patenting has had real effects on
the direction of scientific progress" by more closely tying research and development with
commercial interests); David Blumenthal, Academic-Industry Relationships in the Life Sciences:
Extent, Consequences, and Management, 268 J. Am. MED. ASS'N 3344, 3346 (1992) ("Among
respondents to the Harvard project's faculty survey, 30% of biotechnology faculty with industrial
support (compared with 7% without it) said that their choice of research topics had been influenced
by the likelihood that the results would have commercial application.").
86 See WILLIAM M. LANDES & RICHARD A. POSNER, THE ECONOMIC STRUCTURE OF INTELLECTUAL
PROPERTY LAW 316 (2003) ("Being able to earn substantial income from patent licensing has, it

appears, induced universities to substitute away from basic research, and the result may have been a
net social loss."); Rebecca S. Eisenberg, Public Research and Private Development: Patents and
Technology Transfer in Government-SponsoredResearch, 82 VA. L. REV. 1663, 1669-70 (1996);
see also Katherine J. Strandburg, Curiosity-DrivenResearch and University Technology Transfer,
in UNIVERSITY ENTREPRENEURSHIP AND TECHNOLOGY: PROCESS, DESIGN, AND INTELLECTUAL

PROPERTY 93, 111 (Gary D. Libecap ed., 2005) ("The strongest motivation for a basic researcher to
skew her research direction in an effort to obtain a patent is probably the possibility of industrial
research funding.").
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continue to be studied. 87 This issue can have an impact on developing countries
because it might lead to a decrease in the use of research funds to support
research agendas that may lack a viable 88commercial market but that have a
substantial impact on developing countries.
The authors caution that the benefits of the Bayh-Dole Act may not occur in
developing countries that adopt similar legislation.8 Some of the reasons include
that "[t]he Bayh-Dole Act [was] built on a vibrant history of university-industry
collaboration" that is likely absent in developing countries; biomedical and
biotechnology advances that are patentable in the United States may not be
patentable under the laws of developing countries; the established intellectual
property system, infrastructure and investment in biotechnology research and
development that exist in the United States are not likely to be present in
developing countries; and "the scale of the U.S. higher education research
enterprise" is much larger than that in developing countries. 90 A recent policy
report by the Swedish Institute for Growth Policy Studies reviews suggestions for
increasing interaction between university and industry, including: "Making use of
alumni to expand networks into companies[; c]reating offices of economic
development & entrepreneurship[; c]reating boards where deans are represented
along with commercial actors and technology-transfer officers[; and a]rrangin
science presentations for commercial actors with networking opportunities."
Some of these92 suggestions might be successful, depending on the conditions of
each country.
Boettiger and Bennett argue that Bayh-Dole's preference for small
businesses and for manufacturing to occur within the country granting the
funding should be maintained in developing countries because "[e]ncouragement
of local industry and a focus on innovations targeted to domestic needs are both
factors that analysts identify as important for a successful developing country
innovation policy. '93 Boettiger and Bennett also state that a provision focused on
domestic benefit instead of a requirement of "domestic manufacture" may be
''more practical ... for countries that lack research-intensive industries or
manufacturing capability. '94 The developing-country Bayh-Dole Act legislation
should take a tiered approach as to where research and development and
manufacturing of government-funded inventions should take place.
A
modification of this proposal could require first that research and development
with funding from the developing country occur in the developing country for a
domestic benefit, and if that is not possible, then manufacturing of any

87

Boettiger & Bennett, supranote 18, at 267.

88

id.

89 Id. at 272-73.
90 Id.
91NILSSON ET AL., supra note 13, at 42.
92

Boettiger & Bennett, supranote 18, at 273 (raising concerns about the adoption of the Bayh-Dole

Act in developing countries, although "application of these concerns may vary widely and requires
further
analysis at a country-specific level").
93
Id. at 277.
94
Id. at 281.
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commercial application for a domestic benefit should happen in the developing
country. If neither research and development nor manufacturing is possible in
the developing country, then a substantial domestic benefit should be required.
This provision would ensure that government funding is used to the greatest
benefit to the population of the developing country when possible.
Boettiger and Bennett assert there should be an "[a]rticulation of
performance metrics for [technology transfer offices]" and that these metrics
should not be "based on revenue generation, and numbers of patents and licenses
[that] distort[] the decision-making process of [technology transfer office]
9
staff., 95 These metrics "should be integrated into the policy ... framework."
The use of such metrics is particularly helpful because most revenue generated
from licensing comes from a limited number of licenses. 97 In fact, "[t]he top five
income-generating licenses account for 76 percent of the total income that [U.S.]
universities get from licensing. 98, A system that primarily uses the amount of
licensing revenue as a measure of success is problematic, given the fact that most
technology transfer offices operate at a loss.99 Moreover, a system that utilizes
the number of patents obtained and licenses executed is less likely to be
concerned with ensuring that some technology remains in the public domain. A
new performance metrics system could include the number of publications,
number of commercial products and services introduced to the public, general
economic growth, and new jobs.'00
Developing countries may also consider using the lure of government
funding to obtain favorable pricing for pharmaceuticals or other inventions
developed by private industry using government-funded patented inventions.
This issue has been considered by a public policy study group tasked with
providing recommendations for the treatment of state-government-funded
inventions and rejected by the group because of the apparent failure of the
National Institutes of Health to obtain favorable pricing through the use of
Cooperative Research and Development Agreements.'0 1

95

Id.at 280.
Id.
97NILSSON ET AL., supra note 13, at 11.
96

98

Id.

99 Id.at 16; Powers, supra note 5, at B 18.
100
NILSSON ET AL., supra note 13, at 15 (noting that developing metrics that all interested parties,
including universities, market actors, and politicians, can agree upon is difficult).
In recognition of the long odds against discovery of a profitable product, and because
getting a new product to the market often requires 10 to 15 years of development and
testing, the [International Cooperative Biodiversity Group (ICBG)] programs
emphasize income derived by local people from the process of exploration and
discovery rather than on the promise of huge royalties that may never materialize.
J.Michael Finger, Introduction and Overview, in POOR PEOPLE'S KNOWLEDGE: PROMOTING
INTELLECTUAL PROPERTY INDEVELOPING COUNTRIES 1, 21 (J.
Michael Finger & Philip Schuler ed.,
2004).
101
CCST INTERIM REPORT, supra note 23, at 9-10.
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Another possible modification to the Bayh-Dole Act scheme -is to require a
revenue stream back to the government, to be used for additional research and
development grants and public health needs. 0 2 In the case where the traditional
knowledge of a particular group within a developing country is utilized to
develop a commercial application, the Bayh-Dole Act scheme in the developing
country could require a revenue stream to the particular group that possesses the
helpful traditional knowledge. In proposing that an "International Bayh-Dole"
should be established to address concerns with biopiracy and attract foreign
direct investment to developing countries, one commentator has argued that,
While advantageous to business by providing clear rights to inventions
derived from indigenous knowledge and potentially advantageous to
developing countries who wish to attract foreign direct investment, the BayhDole system does little to acknowledge the contributions that indigenous
peoples make in the derivation of the inventions and to ensure that they will
receive the benefits from their [traditional knowledge].10 3
In adopting legislation similar to the Bayh-Dole Act, developing countries
could overcome this problem by explicitly requiring a royalty stream to
indigenous groups who possess traditional knowledge used to develop a
commercial application along with an acknowledgement of the contribution of
the indigenous group. However, properly allocating royalties to whoever may
"possess" the traditional knowledge or biodiversity resources may prove
difficult.) °4
An additional concern for developing countries is to determine how to
allocate rights to inventions developed from research projects that use funding
from multiple sources. Developing countries could provide different rules for
allocation depending upon the sources of funding for a particular project.
Developing countries should also include consequences for noncompliance with
the Bayh-Dole-type reporting requirements.' 0 5 Consequences for noncompliance
could include the right of the developing country to revoke intellectual property
rights in the government-funded invention through such mechanisms as "marchin rights" and to deny future funding to the particular researcher or institution.'0 6

102
103

Id. at 39-40.
Heather A. Sapp, Monopolizing Medicinal Methods: The Debate Over Patent Rights for

IndigenousPeoples, 25 TEMP. J. SCi. TECH. & ENVTL. L. 191, 212 (2006).
104 See Cynthia M. Ho, Biopiracy and Beyond: A Consideration of the Socio-Cultural Conflicts
with Global Patent Policies, 39 U. MICH. J.L. REFORM 433, 463 (2006) ("[A]lthough it is true that
some Samoan people[, who are entitled to receive some compensation,] assisted Western
researchers in what ultimately resulted in a patented product, the native tree, the Mamala, grows
throughout tropical forests in the South Pacific, such that it is possible that other indigenous
communities may feel excluded.").
105
See Mireles, supra note 5, at 1205.
10 6 Id.
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III. A POTENTIAL CONSEQUENCE FROM ADOPTING
LEGISLATION SIMILAR TO THE BAYH-DOLE ACT?
This article argues that one possible consequence that may arise from
developing countries adoption of legislation similar to the Bayh-Dole Act is that
research agendas at local universities may be directed to developing governmentfunded inventions that are focused on solving local needs through public-private
collaborations. Some commentators have suggested that the Bayh-Dole Act has
contributed to a skewing of research agendas to issues with commercial
markets-including primarily the needs of developed countries-and away from
possibly solving issues that confront developing countries. 10 7 Boettiger and
Bennett point out that there is insufficient empirical evidence to date on this
topic. 108
This issue is critically important to understanding the impact of the BayhDole Act's adoption not only in the United States, but also in developed countries
throughout the world who seek to capture similar economic benefits that the Act
has allegedly produced for the United States. Channeling government funding
towards local needs and using private-public collaborations could provide
solutions to local humanitarian issues and bridge the funding gap caused by a
possible shift in focus to the needs of developed countries.'u 9 Universities in
developing countries could also use the government funding to take advantage of
local biodiversity resources" and indigenous medicinal knowledge" in

107Boettiger
0

& Bennett, supra note 18, at 265-67.
' ' Id. at 267.
109Private companies may have an incentive to develop technology to solve local needs.

Cf.

Finger, supra note 1000, at 4 (Developed country negotiators argue that "[i]f developing countries
enforced IPRs as the TRIPS Agreement specifies,... industrial country companies would have an
incentive to create products aimed at problems, such as tropical diseases, that were of particular
concern to developing countries.").
110Brazil is one example of a developing country with tremendous biodiversity resources. See
Ferrer et al., supra note 822, at DC8 ("Brazil's terrestrial biodiversity, with numerous biomes
including the Cerrado, Amazon rainforest, Pantanal wetlands, Caatinga region, and Araucaria and
Atlantic forests, is also unrivaled in the South American continent and probably elsewhere. This
combination of natural and scientific resources gives the country great potential to promote health
biotechnology.").
111The terms "indigenous people" and "traditional knowledge" have been defined in different
ways. One source defines "indigenous peoples" as "'existing descendants of non-Western peoples
who in general continue to occupy their ancestral lands even after conquest by Westerners, or who
have been relocated forcibly in the process of colonization"' and "traditional knowledge" as "'the
body of historically constituted knowledge instrumental in the long-term adaptation of human
groups."' Sapp, supra note 1033, at 195 (quoting Trevor W. Purcell, Indigenous Knowledge and
Applied Anthropology: Questions of Definition and Direction, 57 HUM. ORG. 258, 259-60 (1998)).
This same source defines "indigenous medicinal knowledge" as "a subset of [traditional
knowledge] 'consisting of the medicinal and curative properties of plants in indigenous culture,'
including genetic resources." Id. (quoting John L. Trotti, Compensation Versus Colonization: A
Common Heritage Approach to the Use of Indigenous Medicine in Developing Western
Pharmaceuticals,56 FOOD & DRUG L.J. 367, 369 (2001)). See also STEPHEN A. HANSEN & JUSTIN
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partnership with the local population, and to commercialize those resources if
desired."'I Interestingly, one commentator has suggested that,
[e]ssentially, the bio-diverse developing countries are facing today the same
situation that the U.S. faced in the 1970s. They possess a tremendous
unexploited potential value in natural products R&D, but, without the proper
legal framework needed to ensure the commercial development 3of actual
products, their economic and health objectives will not be realized."
As noted earlier, however, developing countries are widely diverse in terms
of the availability of resources and their ability to commercially exploit those
resources. 114 Many developing countries---especially those that have been
categorized as least developed countries by the United Nations-are unlikely to
benefit from legislation similar to the Bayh-Dole Act.
Some developing countries have already been successful in focusing on and
addressing local needs through research and development. "For example, South
Africa is responding to the HIV/AIDS pandemic by prioritizing research on the
disease; it is promoting the development of a vaccine against HIV subtype C, the
strain most prevalent in that country (as well as in the rest of Africa and
Asia)."' 1 5 In Brazil, researchers at the federal University at Minas Gerais and a
Brazilian pharmaceutical firm "developed and patented a process for

W. VANFLEET, AM. Ass'N FOR THE ADVANCEMENT OF SCIENCE, TRADITIONAL KNOWLEDGE AND
INTELLECTUAL PROPERTY: A HANDBOOK ON ISSUES AND OPTIONS FOR TRADITIONAL KNOWLEDGE
HOLDERS IN PROTECTING THEIR INTELLECTUAL PROPERTY AND MAINTAINING BIOLOGICAL

DIVERSITY 3 (2003), availableat http://shr.aaas.org/tek/handbook/handbook.pdf (last visited Jan. 5,
2008) (defining "traditional knowledge" as "the information that people in a given community,
based on experience and adaptation to a local culture and environment, have developed over time,
and continue to development").
112 See Paul Gepts, Who Owns Biodiversity, and How Should the Owners be Compensated?,
134
PLANT PHYSIOLOGY 1295, 1298 (2004) ("Genetic diversity is unevenly distributed around the
planet, with most of the diversity located in tropical and subtropical regions, where most
developing countries are located."). The government in China has identified biotechnology as a
specific target for development and "this new approach is expected to develop and commercialize
indigenous health biotechnology products that are internationally competitive." Li Zhenzhen et al.,
Health Biotechnology in China-Reawakening of a Giant, 22 NATURE BIOTECH. DC13, DCI5
(2004).
A current example of a country utilizing biodiversity resources to produce
biopharmaceutical products is Cuba. See Halia Thorsteinsd6ttir et al., Cuba-Innovation Through
Synergy, 22 NATURE BIOTECH. DC 19, DC19 (2004) ("Cuba is developing natural products based on
the island's flora. An example is the natural anticholestoral drug policosanol (PPG), an 8-alcohol
extract derived from the wax of one of the country's main crops, sugarcane.").
113 Sapp, supra note 1033, at 212. (quoting Susan Kling Finston, Relevance of Genetic Resources
to the Pharmaceutical Industry I (Dec. 2, 2004) (unpublished manuscript, presented at the D.C.
Bar Convention on Biological Diversity)).
114 Cuba is an example of a country with a well-developed biotechnology sector and
the ability to
exploit it. Interestingly, Cuba has filed over 500 patent applications on 200 products in the health
biotechnology field and "exports biotechnology products to more than 50 countries, mainly in Latin
America, Eastern Europe and Asia." Thorsteinsd6ttir et al., supra note 1122, at DC 19.
"5 Thorsteinsd6ttir et al., supra note 822, at DC48.
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recombinant human insulin."' 16 Researchers in Brazil at the federal FIOCRUZ
institute have also developed an attenuated virus to treat yellow fever and
recombinant antigens to deal with Chagas disease. 1 7 India has developed a
hepatitis B vaccine, which it sells within India and to the United Nations
Children Foundation." 8 Researchers in Cuba developed a meningitis B vaccine
and created "the world's first human vaccine with a synthetic antigen for
Haemophilus influenzea type b." 119 Researchers in Egypt were able to develop
recombinant insulin 120 and diagnostics for clinical use for hepatitis C, "the fastest
growing infectious disease [in Egypt].''
Moreover, researchers in Thailand
developed a method to treat drug resistant malaria that recently received a U.S.
patent.
Moreover, researchers tend to publish articles in scientific journals on

116

Ferrer, supra note 822, at DC8.

"7 Id. at DC9. FIOCRUZ was founded to develop treatments for bubonic plague, yellow fever, and

smallpox. Id. at DC 10. Notably, the FIOCRUZ institute "also runs a manufacturing plant... that
has vaccine and diagnostics production facilities." Id.
"18Thorsteinsd6ttir et al., supra note 822, at DC48; see Nandini K. Kumar et al., Indian
Biotechnology--Rapidly Evolving and Industry Led, 22 NATURE BIOTECH. DC3 1, DC31 (2004)
("One of the biggest successes ... was India's first indigenously developed hepatitis B vaccine...
."1).

119 Thorsteinsd6ttir et al., supra note 1122, at DC19. Some current research in Cuba includes
"research on recombinant Dengue vaccine, preventative and therapeutic AIDS vaccines, cholera
vaccine and a cancer therapeutic vaccine." Id. Additional biotechnology products developed by
Cuba include other vaccines, therapeutics, and diagnostics. Id. at DC20. Some of the vaccines are
purified meningococci for meningitis B and C, and synthetic Hib for pneumonia and meningitis.
Id. Table 1. The therapeutics include recombinant streptokinase for cardiovascular disease,
recombinant IFN-ct for viral infections and ocological diseases, recombinant epideral growth factor
for burns and ulcer healing, recombinant granulocyte colony-stimulating factor for leukopenia and
neutropenia, MAb to CD3 for organ transplant rejection, recombinant erythropoietin-a for anemia,
humanized MAb against epidermal growth factor receptor for head and neck tumors, and
ateromixol for anti-cholesterol application. Id. Diagnostics include miniaturized enzyme-linked
immunosorbent assay kits for AIDS, blood certification, and prenatal diagnosis; radiolabeled mAbs
targeting various cancer markers for cancer imaging; and enzyme-linked immunosorbent assays for
syphilis and celiac disease. Id.
120 Thorsteinsd6ttir et al., supra note 822, at DC48.
121Basma Abdelgafar et al., The Emergence of Egyptian Biotechnologyfrom Generics, 22 NATURE

BIOTECH. DC25, DC25 (2004).
122

Thai Team Gets US Patentfor Malaria Drugs Breakthrough, BANGKOK POST, June 19, 2007.

Researchers in developing countries such as "Argentina, Brazil, China, Cuba, Egypt, India, Mexico
and South Africa" have been conducting research on a wide range of crops, including "banana,
cassava, cowpea, plantain, rice and sorghum" and some "developing countries will soon have new
[genetically modified) crops available such as virus-resistant papaya, sweet potato and cassava as
well as rice tolerant to abiotic stresses (salinity and drought)." Food and Agriculture Organization
of the United Nations, Biotechnology: Several Developing Countries Now Have Well-Developed
Programmes , http://www.fao.org/newsroom/en/news/2005/102236/index.html (last visited Jan. 5,
2008).
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local health issues. 123 In Brazil, researchers publish on tropical diseases which
have a large impact on its population. 24 South African researchers publish
heavily on virology, which includes HIV/AIDS.125 Researchers in South Africa
and Brazil are utilizing indigenous medicinal knowledge and biodiversity
resources in the search for solutions to local problems. 126 Notably, the countries
listed in these examples invented and developed technologies used to solve local
problems apparently without the need for legislation similar to the Bayh-Dole
Act to spur commercialization. However, passage of legislation similar to BayhDole may lead to an increase of such activity as more government and private
resources are diverted to developing government-funded technology. Bayh-Dole
legislation may enable university researchers to utilize private expertise and
funding, and may increase the likelihood of the development of products and
services to address local needs. In a best-case scenario, local companies may be
created to license and further develop research developed in universities utilizing
government funding.
Some developing countries have also been successful in licensing
government-funded technology. For example, Singapore's Agency for Science,
Technology and Research is responsible for the funding and development of
twelve public research institutes and its commercial licensing arm, Exploit
Technologies, has "licensed more than 80 cutting edge technologies (in ...
science, engineering and biomedical sciences) to companies which cover the
wide spectrum from small and medium enterprises to multinationals, thus
providing them with a competitive edge to stay ahead in the global biotechnology
race." 27 In Indonesia, the Kekayaan Intelektual dan Alih Teknologi [KIAT], a

123"Furthermore, preliminary analysis of scientometric data suggests that some of the seven case

study countries publish predominately in scientific fields relevant to the health problems within
their own countries." Thorsteinsd6ttir et al., supra note 822, at DC48 (citation omitted).
124 Id.
125

Id.

126 Id. at DC50.

Notably, India is attempting to "draw from a rich heritage of traditional

knowledge, and a genetically diverse population." Kumar et al., supra note 11818, at DC36. A
recent collaborative agreement "entails the Department of [Ayruveda, Yoga & Naturopathy, Unani,
Siddha, and Homeopathy (AYUSH)] identifying traditional formulations, the [Council for
Scientific and Industrial Research (CSIR)] conducting the pre-clinical toxicological studies, and the
[Indian Council of Medical Research (ICMR)] carrying out clinical trials to test it." Id.
127 Morley Muralitharan, Snapshot of Singapore: Biotechnology Boom
Indicators, 10 ASIA PAC.
BIOTECH NEWS 402, 402-03 (2006). Notably, Singapore is quickly establishing itself as a leader in
biotechnology in Asia and is developing the needed infrastructure and human capital resources to
succeed. Indeed, Singapore's biomedical services industry manufacturing output increased to
$11.3 billion (U.S.) in 2005 from its initial launch in 2000. Sheo S. Rai, Overview of the BMS
Industry, 10 ASIA PAC. BIOTECH NEWS 404, 404 (2006). Singapore also offered over $18.2 million
(U.S.) in-grants to research institutes and hospitals. Chan Yiu Lin, The Buzz in Singapore's Biotech
Industry, 10 ASIA PAC. BIOTECH NEWS 407, 407 (2006). "In February 2006, Bio*One Capital and
the Lonza Group announced that they are jointly building a large-scale mammalian cell culture
plant in Singapore for the manufacture of commercial biopharmaceuticals, totaling an investment
of US$250 million." Id. at 411. Moreover, local companies have even developed avian flu
diagnostic kits. Id. Employment in the biomedical services industry in Singapore in 2006 was
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technology transfer office, was formed as "part of the Indonesian Agricultural
Research Foundation, a private non-profit organization established by the
national government to facilitate technology transfer, licensing and
commercialization of agricultural technologies.""' The KIAT has entered into
numerous negotiations for licenses to commercialize bio-fertilizer, biobactericide, and hybrid maize, and has licensed "Rhizobium based bio-fertilizer
for soybean s] to a private company, for production and sale throughout
Indonesia. , 12 India, in particular, has been successful in developing commercial
applications from traditional knowledge and then transferring that technology to
private companies for commercialization. 3 0 Development of the drug Jeevani
through collaboration with the Kani serves as a particularly good example:
The Kani are an ethnic group of some 16,000 people who live in
southwestern India. Working primarily with three Kani consultants, the
Tropical Botanical Garden and Research Institute (TBGRI) of India learned
of the antifatigue properties of a wild plant. From this plant the TBGRI
developed the drug Jeevani. When the TBGRI transferred manufacturing
rights to Aryavaidya Pharmacy Coimbatore Ltd., TBGRI agreed to share 5050 the license and royalty income with the Kani. It took a while for the
various Kani clans to agree, but in time they established the Kerala Kani

Samudaya Kshema Trust to manage this income.
Through 2001, the Trust Society-fully managed by Kani-has received
1,345,000 Indian rupees (about US$30,000) of royalties and fees .... The
Trust Society has funded various self-employment schemes for unemployed
Kani youth and has provided special financial assistance of IRs 25,000 for the
welfare of two tribal children whose mother was killed by a wild elephant. It
also paid IRs 50,000 to3 the three Kani consultants who initially provided the
knowledge to TBGRI.1 1
In another case, the San community, hunter-gathers in South Africa, will be
paid a percentage of the royalties and milestone payments received by the
licensor, the South African Council for Scientific and Industrial Research, from

the licensee, Phytopharm, a United Kingdom-based company, for an anti-obesity
drug derived from the Hoodia plant. 1 2 Interestingly, Cuba has engaged in
10,200. Lionel Lau, Boom Time for Biomedical Sciences in Singapore: A Perspectivefrom an
EducationalInstitute, 10 ASIA PAC. BIOTECH NEWS 413, 413 (2006). Singapore attracted over $500
million (U.S.) in investments in its biomedical services industry in both 2004 and 2005. Id. at 414.
Despite this success, private venture capital investment is still low. Morley Muralitharan et al.,
Survey Commentaries and Analysis on Singapore Biotechnology Venture Capital,Intellectual and
Property Regulatory Law, 10 ASIA PAC. BIOTECH NEWS 442, 442-43 (2006). One reason for the

low private venture capital investment is the relative lack of experienced intellectual property legal
personnel. Id. at 443.
128Maredia et al., supra note 811, at 18.
129 Id.

130

See Finger, supranote 1000, at 20.

131Id.
132 See

Tamar Kahn, Indigenous Group to Share Royalties on Anti-Obesity Drug, ScI. & DEV.

Mar.
26,
2003,
http://www.scidev.net/News/
index.cftn?fuseaction=readNews&itenid=355&language=l (last visited Jan. 5, 2008). Notably,

NETWORK,
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commercial collaborations to manufacture and distribute its meningitis vaccine
with GlaxoSmithKline in Europe and North America and manufacture its
hepatitis B vaccine with an Indian firm, Panacea Biotec.' 33 Cuba has also entered
a joint venture with a Canadian firm to develop and market cancer therapeutics
and made an agreement with the U.S. firm, CancerVax, to develop and license
cancer vaccines.' 34 While these examples may be atypical, they do provide
evidence of the possibility of addressing local needs and other issues through the
transfer of government-funded inventions developed sometimes with the aid of
indigenous and biodiversity resources to private companies. Legislation similar
to the Bayh-Dole Act adopted in developing countries may facilitate technology
transfer that results in a redirection of research agendas toward addressing local
needs and may also channel attention to the commercialization of local resources.
However, for most developing countries the conditions necessary to recreate the
purported impact of the Bayh-Dole Act in the United States are not present.
IV. CONCLUSION
If developing countries adopt legislation similar to the Bayh-Dole Act, they
should make modifications to the Act to tailor it to their local conditions and to
address potential problems identified by examining the impact of the Bayh-Dole
Act in the United States. The question of whether developing countries that
enact legislation similar to Bayh-Dole will receive a similar purported impact
that has occurred in the United States is unclear. However, adopting that
legislation may result in the direction of government funding to providing
solutions to local needs.

"[o]nly after a public outcry about the lack of benefit sharing with the San was a deal brokered that
pledged a percentage of the royalties to them." Talent Ngandwe, African "Biopiracy" Debate
Heats Up, Sci. & DEV. NETWORK, Feb. 2, 2006, http://www.scidev.net/content/news/eng/africanbiopiracy-debate-heats-up.cfm (last visited Jan. 5, 2008). For additional discussion of the
agreement with the San concerning the Hoodia plant, see Marion Motari et al., South AfricaBlazing a TrailforAfrican Biotechnology, 22 NATURE BIOTECH. DC37, DC38 (2004).
133 Thorsteinsd6ttir et al., supra note 1122, at DC23.
134 id.

